Repligen Corporation

NasdaqGS:RGEN 주식 보고서

시가총액: US$8.0b

Repligen 미래 성장

Future 기준 확인 4/6

Repligen (는) 각각 연간 51.4% 및 12.9% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 51.1% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 4.9% 로 예상됩니다.

주요 정보

51.4%

수익 성장률

51.1%

EPS 성장률

Life Sciences 수익 성장18.4%
매출 성장률12.9%
향후 자기자본 수익률4.9%
애널리스트 커버리지

Good

마지막 업데이트20 Nov 2024

최근 미래 성장 업데이트

Repligen Corporation Just Missed Earnings - But Analysts Have Updated Their Models

May 03
Repligen Corporation Just Missed Earnings - But Analysts Have Updated Their Models

Recent updates

Repligen Corporation's Earnings Preview: Expensive With Mixed Growth Prospects

Nov 12

Repligen (NASDAQ:RGEN) Has A Pretty Healthy Balance Sheet

Nov 08
Repligen (NASDAQ:RGEN) Has A Pretty Healthy Balance Sheet

Is It Time To Consider Buying Repligen Corporation (NASDAQ:RGEN)?

Oct 14
Is It Time To Consider Buying Repligen Corporation (NASDAQ:RGEN)?

Repligen Corporation's (NASDAQ:RGEN) Intrinsic Value Is Potentially 28% Above Its Share Price

Sep 08
Repligen Corporation's (NASDAQ:RGEN) Intrinsic Value Is Potentially 28% Above Its Share Price

Repligen Corporation (NASDAQ:RGEN) Stocks Shoot Up 27% But Its P/S Still Looks Reasonable

Jul 31
Repligen Corporation (NASDAQ:RGEN) Stocks Shoot Up 27% But Its P/S Still Looks Reasonable

We Think Repligen (NASDAQ:RGEN) Can Stay On Top Of Its Debt

Jul 15
We Think Repligen (NASDAQ:RGEN) Can Stay On Top Of Its Debt

Repligen: Strong Filtration Growth, Offset By Other Challenges

Jul 13

Why We're Not Concerned Yet About Repligen Corporation's (NASDAQ:RGEN) 27% Share Price Plunge

Jun 14
Why We're Not Concerned Yet About Repligen Corporation's (NASDAQ:RGEN) 27% Share Price Plunge

Is Now The Time To Look At Buying Repligen Corporation (NASDAQ:RGEN)?

Jun 10
Is Now The Time To Look At Buying Repligen Corporation (NASDAQ:RGEN)?

Repligen Stock: Still Quite Overvalued

May 30

Repligen Corporation Just Missed Earnings - But Analysts Have Updated Their Models

May 03
Repligen Corporation Just Missed Earnings - But Analysts Have Updated Their Models

Estimating The Intrinsic Value Of Repligen Corporation (NASDAQ:RGEN)

Apr 30
Estimating The Intrinsic Value Of Repligen Corporation (NASDAQ:RGEN)

Repligen (NASDAQ:RGEN) Has A Pretty Healthy Balance Sheet

Apr 15
Repligen (NASDAQ:RGEN) Has A Pretty Healthy Balance Sheet

At US$206, Is Repligen Corporation (NASDAQ:RGEN) Worth Looking At Closely?

Feb 13
At US$206, Is Repligen Corporation (NASDAQ:RGEN) Worth Looking At Closely?

Estimating The Intrinsic Value Of Repligen Corporation (NASDAQ:RGEN)

Jan 08
Estimating The Intrinsic Value Of Repligen Corporation (NASDAQ:RGEN)

Why We're Not Concerned About Repligen Corporation's (NASDAQ:RGEN) Share Price

Dec 19
Why We're Not Concerned About Repligen Corporation's (NASDAQ:RGEN) Share Price

What Does Repligen Corporation's (NASDAQ:RGEN) Share Price Indicate?

Nov 01
What Does Repligen Corporation's (NASDAQ:RGEN) Share Price Indicate?

Is Repligen (NASDAQ:RGEN) Using Too Much Debt?

Oct 17
Is Repligen (NASDAQ:RGEN) Using Too Much Debt?

Is There An Opportunity With Repligen Corporation's (NASDAQ:RGEN) 22% Undervaluation?

Sep 29
Is There An Opportunity With Repligen Corporation's (NASDAQ:RGEN) 22% Undervaluation?

Things Look Grim For Repligen Corporation (NASDAQ:RGEN) After Today's Downgrade

Aug 09
Things Look Grim For Repligen Corporation (NASDAQ:RGEN) After Today's Downgrade

Does Repligen (NASDAQ:RGEN) Have A Healthy Balance Sheet?

Jul 17
Does Repligen (NASDAQ:RGEN) Have A Healthy Balance Sheet?

Is There Now An Opportunity In Repligen Corporation (NASDAQ:RGEN)?

Jul 03
Is There Now An Opportunity In Repligen Corporation (NASDAQ:RGEN)?

With EPS Growth And More, Repligen (NASDAQ:RGEN) Makes An Interesting Case

Jun 19
With EPS Growth And More, Repligen (NASDAQ:RGEN) Makes An Interesting Case

수익 및 매출 성장 예측

NasdaqGS:RGEN - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜수익수익잉여 현금 흐름작전 현금평균 애널리스트 수
12/31/20268027015718710
12/31/20256974710216215
12/31/2024634169415616
9/30/2024634-8131165N/A
6/30/20246209119155N/A
3/31/202462024110147N/A
12/31/20236323675114N/A
9/30/202365310197147N/A
6/30/202371212451149N/A
3/31/202376115446160N/A
12/31/202280218639172N/A
9/30/202280116615160N/A
6/30/202277915941141N/A
3/31/202273414642133N/A
12/31/202167112848119N/A
9/30/20215931193584N/A
6/30/20215091004083N/A
3/31/2021433803262N/A
12/31/2020366603663N/A
9/30/2020327444465N/A
6/30/2020302314266N/A
3/31/2020286234367N/A
12/31/2019270214467N/A
9/30/2019253233455N/A
6/30/2019233273453N/A
3/31/2019210212541N/A
12/31/2018194171933N/A
9/30/2018184233242N/A
6/30/201817123N/A21N/A
3/31/201815529N/A18N/A
12/31/201714128N/A17N/A
9/30/201712521N/A4N/A
6/30/201711318N/A5N/A
3/31/201711013N/A12N/A
12/31/201610512N/A8N/A
9/30/20161007N/A9N/A
6/30/2016968N/A17N/A
3/31/2016888N/A14N/A
12/31/2015849N/A15N/A
9/30/2015789N/A13N/A
6/30/2015748N/A13N/A
3/31/2015687N/A8N/A
12/31/2014648N/A18N/A
9/30/20146312N/A24N/A
6/30/20146616N/A24N/A
3/31/20146818N/A30N/A
12/31/20136816N/A26N/A

애널리스트 미래 성장 예측

수입 대 저축률: RGEN 은 향후 3년 동안 수익을 낼 것으로 예상되며, 이는 절약률( 2.6% )보다 빠른 성장으로 간주됩니다.

수익 vs 시장: RGEN (는) 향후 3년 동안 평균 시장 성장보다 높은 수익을 올릴 것으로 예상됩니다.

고성장 수익: RGEN 향후 3년 내에 수익을 낼 것으로 예상됩니다.

수익 대 시장: RGEN 의 수익(연간 12.9% ) US 시장( 8.9% 보다 빠르게 성장할 것으로 예상됩니다. 8.9% 연간).

고성장 수익: RGEN 의 수익(연간 12.9% )은 연간 20% 보다 느리게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: RGEN 의 자본 수익률은 3년 내에 최저 수준이 될 것으로 예상됩니다( 4.9 %).

성장 기업 발견

7D

1Y

7D

1Y

7D

1Y